Intensive Care Unit, Military Teaching Hospital sainte Anne
Toulon, 83041, France
NCT Number: NCT01218191
The aim of this study is to describe acute neurocardiogenic injury after subarachnoid hemorrhage assessed with cardiac 123I-MIBG scintigraphy and 18F-FDG PET/CT during the first week and the first six months after SAH.
The study hypothesis is that the evolution of the cardiac disturbances follows the clinical evolution.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Toulon, 83041, France
The cardiac metabolic disturbance are assessed by a 18F-FDG PET/CT in the first week after SAH and monthly until normal result.
The myocardial sympathetic innervation is assessed by a cardiac 123I-MIBG scintigraphy in the first week after SAH and six months later.
Clinical outcome is assessed by Glasgow Outcome Scale, modified Rankin Scale and MOS-SF36 at 1, 3 and 6 months after SAH.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: first week after SAH
Time frame: first week after SAH
Time frame: one month after first cardiac 18F-FDG PET
Time frame: Six months after SAH
Direction Centrale du Service de Santé des Armées
Other
Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage Assessed With Cardiac 18F-FDG PET and 123I-MIBG Scintigraphy: a Prospective Observational Study.
Acronym: HSA-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02894034
Brain Diseases, Cardiovascular Diseases
Amiens, France
View Trial DetailsNCT03655509
Brain Diseases, Cardiovascular Diseases
Rennes, France
View Trial DetailsNCT04042571
Brain Diseases, Cardiovascular Diseases
Bordeaux, France
View Trial DetailsNCT06797765
Brain Diseases, Cardiovascular Diseases
Dallas, Texas, United States
View Trial Details